Liu W, Li H. COVID-19: Attacks the 1-Beta Chain of Hemoglobin and Captures the Porphyrin to Inhibit Heme Metabolism. 2020; https://chemrxiv.org/ndownloader/files/22283226
Wen-zhong L, Hua-lan L, Liu W, Li H. COVID-19 Dis-ease: ORF8 and Surface Glycoprotein Inhibit Heme Metabolism by Binding to Porphyrin. 2020; DOI:10.26434/chemrxiv.11938173.v2
Abozeid Y, Ismail NSM, McLean GR, Hamdy NM. A molecular docking study repurposes FDA approved iron oxide nanoparticles to treat and control COVID-19 infection. Eur J Pharm Sci 2020; 153: 105465. DOI: 10.1016/j. ejps.2020.105465
Algassim AA, Elghazaly AA, Alnahdi AS, Mohammed-Rahim OM, Alanazi AG, Aldhuwayhi NA, et al. Prognostic significance of hemoglobin level and autoimmune hemolytic anemia in SARS-CoV-2 infection.Ann Hema-tolDOI: 10.1007/s00277-020-04256-3
Lippi G, Mattiuzzi C. Hemoglobin value may be decreased in patients with severe coronavirus disease 2019. Hematol Transfus Cell Ther 2020; 42(2): 116-117. DOI: 10.1016/j. htct.2020.03.001
Lv Y, Chen L, Liang X, Liu X, Gao M, Wang Q, et al. Association between iron status and the risk of adverse outcomes in COVID-19. Clin Nutr 2020. DOI: 10.1016/j. clnu.2020.11.033
San Juan I, Bruzzone C, Bizkarguenaga M, Bernardo-Seisdedos G, Laín A, Gil-Redondo R, et al. Abnormal concentration of porphyrins in serum from COVID-19 patients. Br J Haematol 2020; 190(5): e265-e267. DOI: 10.1111/bjh.17060
Taneri PE, Gómez-Ochoa SA, Llanaj E, Raguindin PF, Rojas LZ, Roa-Díaz ZM, et al. Anemia and iron metabo-lism in COVID-19: a systematic review and meta-analysis. Eur J Epidemiol 2020; 35(8): 763-773. DOI: 10.1007/s10654-020-00678-5
Torti L, Maffei L, Sorrentino F, De Fabritiis P, Miceli R, Abruzzese E. Impact of SARS CoV-2 in Hemoglobinopathies with Immune Disfunction and Epidemiology. A Protective Mechanism from Beta Chain Hemoglobin Defects? Mediterr J Hematol Infect Dis 2020; 12(1): e2020052-e2020052. DOI: 10.4084/MJHID.2020.052
Karimi M, Haghpanah S, Azarkeivan A, Zahedi Z, Zarei T, Akhavan Tavakoli M, et al. Prevalence and mortality in β-thalassaemias due to outbreak of novel coronavirus disease (COVID-19): the nationwide Iranian experience. Br Haematol 2020; 190(3): e137-e140. DOI: 10.1111/bjh.16911
Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the re-cently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020; 30(3): 269-271. DOI: 10.1038/s41422-020-0282-0
Quiros Roldan E, Biasiotto G, Magro P, Zanella I. The possible mechanisms of action of 4-aminoquinolines (chloroquine/hydroxychloroquine) against SARS-CoV-2 infection (COVID-19): A role for iron homeostasis?Pharmacol Res 2020; 158: 104904. DOI: 10.1016/j. phrs.2020.104904
Perricone C, Bartoloni E, Bursi R, Cafaro G, Guidelli GM, Shoenfeld Y, et al. COVID-19 as part of the hyperferritinemic syndromes: the role of iron depletion therapy. Immunol Res 2020; 68(4): 213-224. DOI: 10.1007/s12026-020-09145-5
Vlahakos VD, Marathias KP, Arkadopoulos N, Vlahakos DV. Hyperferritinemia in patients with COVID-19: An opportunity for iron chelation? Artif Organs 2020; DOI: 10.1111/aor.13812
Dalamaga M, Karampela I, Mantzoros CS. Commentary: Could iron chelators prove to be useful as an adjunct to COVID-19 Treatment Regimens? Metabolism 2020; 108: 154260. DOI: 10.1016/j.metabol.2020.154260
Liu W, Zhang S, Nekhai S, Liu S. Depriving Iron Supply to the Virus Represents a Promising Adjuvant Therapeutic Against Viral Survival. Curr Clin Microbiol Rep 2020:1-7. DOI: 10.1007/s40588-020-00140-w
Abbas A, Mostafa A, Yousof E, Ss A. Use of Iron Chela-tors to Reduce the Severity of COVID-19. 2020; 4: 1042.
Abobaker A. Can iron chelation as an adjunct treatment of COVID-19 improve the clinical outcome? Eur J Clin Pharmacol 2020; 76(11): 1619-1620. DOI: 10.1007/s00228-020-02942-9
Loh D. The potential of melatonin in the prevention and attenuation of oxidative hemolysis and myocardial injury from CD147 SARS-CoV-2 spike protein receptor binding. Melatonin Res 2020; 3(3): 380-416. DOI: 10.32794/mr11250069
Email this article (Login required) 
